Following this transaction, Parlavecchio retains ownership of 145,554 shares, which includes 52,046 shares of common stock and 93,508 RSUs.
Following this transaction, Parlavecchio retains ownership of 145,554 shares, which includes 52,046 shares of common stock and 93,508 RSUs.
Following this transaction, Parlavecchio retains ownership of 145,554 shares, which includes 52,046 shares of common stock and 93,508 RSUs.
In other recent news, Scholar Rock, a biopharmaceutical company, continues to make significant strides towards the commercialization of apitegromab, a potential treatment for spinal muscular atrophy (SMA). The company plans to submit regulatory applications in the first quarter of 2025, with a U.S. launch anticipated in the fourth quarter of the same year. The company is also advancing its cardiometabolic program, with top-line data from the Phase 2 EMBRAZE trial in obesity expected in the second quarter of 2025.
Scholar Rock has been the subject of multiple analyst upgrades following significant developments in its drug trials. H.C. Wainwright increased its price target for Scholar Rock to $50.00, maintaining a Buy rating, while Truist Securities raised its price target for the company to $45.00. BMO Capital Markets adjusted its price target for Scholar Rock to $39.00, maintaining an Outperform rating.
These recent developments highlight Scholar Rock’s consistent efforts to address unmet needs in the medical field, with a U.S. commercial launch of Apitegromab planned for Q4 2025. In addition to its SMA treatment, Scholar Rock is also conducting the EMBRAZE Phase 2 study and developing SRK-439, both aimed at obesity management. The company’s financial position is robust, with sufficient funds to support operations and capital expenditure requirements into the fourth quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.